| Primary |
| Lymphoma |
19.8% |
| Acute Myeloid Leukaemia |
17.7% |
| Multiple Sclerosis |
13.4% |
| Relapsing-remitting Multiple Sclerosis |
6.7% |
| Acute Promyelocytic Leukaemia |
6.4% |
| Secondary Progressive Multiple Sclerosis |
5.9% |
| Non-hodgkin's Lymphoma |
4.6% |
| Breast Cancer Metastatic |
4.1% |
| Prostate Cancer |
4.1% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iv |
3.1% |
| B-cell Lymphoma |
2.8% |
| Acute Lymphocytic Leukaemia |
2.3% |
| Neuromyelitis Optica |
1.5% |
| Myelodysplastic Syndrome |
1.3% |
| Prostate Cancer Metastatic |
1.3% |
| Breast Cancer |
1.0% |
| Neoplasm |
1.0% |
| Product Used For Unknown Indication |
1.0% |
| T-cell Prolymphocytic Leukaemia |
1.0% |
| Chronic Lymphocytic Leukaemia |
0.8% |
|
| Acute Promyelocytic Leukaemia |
22.7% |
| Acute Myeloid Leukaemia |
13.6% |
| Neutropenia |
11.8% |
| Thrombocytopenia |
7.3% |
| Pancytopenia |
5.5% |
| Pyrexia |
4.5% |
| Acute Febrile Neutrophilic Dermatosis |
3.6% |
| Myelodysplastic Syndrome |
3.6% |
| Pneumonia |
2.7% |
| Progressive Multifocal Leukoencephalopathy |
2.7% |
| Pulmonary Alveolar Haemorrhage |
2.7% |
| Sepsis |
2.7% |
| Vomiting |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
| Acute Leukaemia |
1.8% |
| Acute Myelomonocytic Leukaemia |
1.8% |
| Febrile Neutropenia |
1.8% |
| Multi-organ Failure |
1.8% |
| Nausea |
1.8% |
| Neutropenic Sepsis |
1.8% |
|
| Secondary |
| Acute Myeloid Leukaemia |
20.4% |
| B-cell Lymphoma |
11.2% |
| Chronic Lymphocytic Leukaemia |
9.5% |
| Product Used For Unknown Indication |
8.6% |
| Non-hodgkin's Lymphoma |
7.9% |
| Drug Use For Unknown Indication |
5.5% |
| Acute Promyelocytic Leukaemia |
5.4% |
| Diffuse Large B-cell Lymphoma |
5.2% |
| Acute Lymphocytic Leukaemia |
5.1% |
| Prostate Cancer Metastatic |
2.9% |
| Prophylaxis |
2.8% |
| Lymphoma |
2.7% |
| Prostate Cancer |
2.2% |
| T-cell Prolymphocytic Leukaemia |
2.1% |
| Acute Monocytic Leukaemia |
2.0% |
| Breast Cancer |
2.0% |
| Mantle Cell Lymphoma |
1.7% |
| Acute Myeloid Leukaemia Recurrent |
1.0% |
| Infection Prophylaxis |
0.9% |
| Leukaemia |
0.9% |
|
| Myelodysplastic Syndrome |
11.5% |
| Febrile Neutropenia |
8.6% |
| Thrombocytopenia |
8.4% |
| Bacterial Sepsis |
7.4% |
| Acute Myeloid Leukaemia |
6.6% |
| White Blood Cell Count Decreased |
6.4% |
| Cardiac Failure |
5.7% |
| Sepsis |
5.7% |
| Pneumonia |
5.4% |
| Vomiting |
5.4% |
| Neutropenia |
4.7% |
| Off Label Use |
3.9% |
| Progressive Multifocal Leukoencephalopathy |
3.2% |
| Lung Neoplasm Malignant |
2.9% |
| Hepatitis B |
2.7% |
| Septic Shock |
2.7% |
| Death |
2.2% |
| Non-small Cell Lung Cancer |
2.2% |
| Pancytopenia |
2.2% |
| Pleural Effusion |
2.2% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
16.9% |
| Product Used For Unknown Indication |
11.1% |
| B-cell Lymphoma |
8.9% |
| Drug Use For Unknown Indication |
8.5% |
| Chemotherapy |
7.1% |
| Non-hodgkin's Lymphoma |
6.8% |
| Metastases To Bone |
4.9% |
| Multiple Sclerosis |
4.4% |
| Acute Lymphocytic Leukaemia |
4.0% |
| Diffuse Large B-cell Lymphoma |
3.9% |
| Prophylaxis |
3.3% |
| Chronic Lymphocytic Leukaemia |
3.2% |
| Prostate Cancer |
2.8% |
| Acute Promyelocytic Leukaemia |
2.4% |
| Breast Cancer |
2.4% |
| Stem Cell Transplant |
2.2% |
| Prostate Cancer Metastatic |
2.0% |
| Breast Cancer Metastatic |
1.9% |
| Prophylaxis Against Graft Versus Host Disease |
1.7% |
| Acute Lymphocytic Leukaemia Recurrent |
1.6% |
|
| Weight Decreased |
10.2% |
| White Blood Cell Count Decreased |
9.0% |
| Pneumonitis |
6.6% |
| Wheezing |
6.6% |
| Drug Ineffective |
5.4% |
| Oedema Peripheral |
5.4% |
| Progressive Multifocal Leukoencephalopathy |
5.4% |
| Pyrexia |
5.4% |
| Vomiting |
5.4% |
| Myelodysplastic Syndrome |
4.2% |
| Nausea |
4.2% |
| Oesophagitis |
4.2% |
| Sepsis |
4.2% |
| Tooth Extraction |
4.2% |
| Rash |
3.6% |
| Urinary Incontinence |
3.6% |
| Febrile Neutropenia |
3.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.0% |
| Red Blood Cell Count Decreased |
3.0% |
| Septic Shock |
3.0% |
|
